Vera Therapeutics (VERA) Other Accumulated Expenses (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Other Accumulated Expenses data on file, last reported at $3.5 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 148.53% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 148.53% YoY) and the FY2025 annual result came in at $1.9 million, up 782.95% from the prior year.
• Other Accumulated Expenses grew to $3.5 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $3.7 million in Q3 2025 to a low of $174000.0 in Q3 2022.
• A 5-year average of $1.2 million and a median of $622000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses slumped 73.87% — and 2025, when it surged 782.95%.
• Tracing VERA's Other Accumulated Expenses over 5 years: stood at $295000.0 in 2022, then soared by 90.85% to $563000.0 in 2023, then plunged by 61.46% to $217000.0 in 2024, then soared by 782.95% to $1.9 million in 2025, then jumped by 80.95% to $3.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $3.5 million (Q1 2026), $1.9 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.